Performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 11 07 2020
accepted: 27 11 2020
entrez: 11 1 2021
pubmed: 12 1 2021
medline: 20 1 2021
Statut: epublish

Résumé

To respond to the urgent need for COVID-19 testing, countries perform nucleic acid amplification tests (NAAT) for the detection of SARS-CoV-2 in centralized laboratories. Real-time RT-PCR (Reverse transcription-Polymerase Chain Reaction), used to amplify and detect the viral RNA., is considered, as the current gold standard for diagnostics. It is an efficient process, but the complex engineering required for automated RNA extraction and temperature cycling makes it incompatible for use in point of care settings [1]. In the present work, by harnessing progress made in the past two decades in isothermal amplification and paper microfluidics, we created a portable test, in which SARS-CoV-2 RNA is extracted, amplified isothermally by RT-LAMP (Loop-mediated Isothermal Amplification), and detected using intercalating dyes or fluorescent probes. Depending on the viral load in the tested samples, the detection takes between twenty minutes and one hour. Using a set of 16 pools of naso-pharyngal swab eluates, we estimated a limit of detection comparable to real-time RT-PCR (i.e. 1 genome copies per microliter of clinical sample) and no cross-reaction with eight major respiratory viruses currently circulating in Europe. We designed and fabricated an easy-to-use portable device called "COVIDISC" to carry out the test at the point of care. The low cost of the materials along with the absence of complex equipment will expedite the widespread dissemination of this device. What is proposed here is a new efficient tool to help managing the pandemics.

Identifiants

pubmed: 33428641
doi: 10.1371/journal.pone.0243712
pii: PONE-D-20-21366
pmc: PMC7799764
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0243712

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2012;7(2):e31432
pubmed: 22384022
Trends Biotechnol. 2011 May;29(5):240-50
pubmed: 21377748
J Virol Methods. 2015 Mar;214:37-42
pubmed: 25681524
Angew Chem Int Ed Engl. 2007;46(8):1318-20
pubmed: 17211899
J Virol Methods. 2017 Jun;244:32-38
pubmed: 28242293
Lab Chip. 2017 Mar 29;17(7):1270-1279
pubmed: 28271104
Anal Chem. 2009 Aug 15;81(16):7091-5
pubmed: 20337388
J Vis Exp. 2018 Sep 14;(139):
pubmed: 30272674
J Clin Microbiol. 1990 Mar;28(3):495-503
pubmed: 1691208
Anal Chem. 2012 Mar 20;84(6):2883-91
pubmed: 22390675
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24450-24458
pubmed: 32900935
Lab Chip. 2012 Jan 7;12(1):174-81
pubmed: 22068336
Anal Chem. 2016 Apr 5;88(7):3562-8
pubmed: 26980448
Angew Chem Int Ed Engl. 2016 Dec 5;55(49):15250-15253
pubmed: 27554333
Sci Rep. 2017 Mar 20;7:44778
pubmed: 28317856
Nucleic Acids Res. 2000 Jun 15;28(12):E63
pubmed: 10871386
Sci Rep. 2017 May 2;7(1):1347
pubmed: 28465576
mSphere. 2021 May 19;6(3):
pubmed: 34011690
RSC Adv. 2014 Jan 1;4(80):42245-42251
pubmed: 25309740
Cold Spring Harb Symp Quant Biol. 1986;51 Pt 1:263-73
pubmed: 3472723
Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):4834-4842
pubmed: 30782834
Anal Chim Acta. 2014 Jan 27;809:117-22
pubmed: 24418141
Anal Sci. 2016;32(3):371-4
pubmed: 26960621
PLoS One. 2020 Jun 12;15(6):e0234682
pubmed: 32530929
Anal Chem. 2015 Aug 4;87(15):7595-601
pubmed: 26104869
Lab Chip. 2017 Jul 11;17(14):2347-2371
pubmed: 28632278
PLoS One. 2013 Sep 30;8(9):e75616
pubmed: 24098705

Auteurs

Pierre Garneret (P)

ESPCI PSL, CBI, IPGG, Paris, France.

Etienne Coz (E)

ESPCI PSL, CBI, IPGG, Paris, France.

Elian Martin (E)

ESPCI PSL, CBI, IPGG, Paris, France.

Jean-Claude Manuguerra (JC)

Institut Pasteur, Paris Cedex, France.

Elodie Brient-Litzler (E)

Institut Pasteur, Paris Cedex, France.

Vincent Enouf (V)

Institut Pasteur, Paris Cedex, France.

Jean-Christophe Olivo-Marin (JC)

Institut Pasteur, Paris Cedex, France.

Fabrice Monti (F)

ESPCI PSL, CBI, IPGG, Paris, France.

Sylvie van der Werf (S)

Institut Pasteur, Paris Cedex, France.

Jessica Vanhomwegen (J)

Institut Pasteur, Paris Cedex, France.

Patrick Tabeling (P)

ESPCI PSL, CBI, IPGG, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH